We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Greater Controls Recommended for Genetic Testing

By LabMedica International staff writers
Posted on 24 Jun 2009
Print article
Public and private agencies calling for greater control of genetic testing have given rise to recommendations for new directives.

Evaluation of genomic applications in practice and prevention (EGAPP) is a project initiated by the CDC Office of Public Health Genomics some years ago. The project's goal is to establish and evaluate a systematic, evidence-based process for assessing genetic tests and other applications of genomic technology, in transition from clinical and public health practice to research. EGAPP published an article in the online edition of the journal Genetics in Medicine in January 2009, which described the group's methodology.

Guidelines, published by the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) in 2009, focus on molecular diagnostic companies, and medical and public health professionals who evaluate lab practices and policies.

New York State (USA) has introduced regulations for companies offering direct to consumer genetic testing programs. These have been added to a growing list of public and private agency demands for regulation of genetic testing, laboratory developed tests (LDTs), and in vitro diagnostic multivariate index assays (IVDMIAs).

The new reports belong to a growing list of those focused on bringing genetic testing performance on par with conventional diagnostic tests. Meanwhile, the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH, Bethesda, MD, USA), announced the latest round of grant awards totaling more than US $13.3 million. These awards are aimed at speeding the development of innovative sequencing technologies that reduce the cost of DNA sequencing, and expand the use of genomics in health care and medical research.

"There has been significant progress over the last several years to develop faster and more cost-effective sequencing technologies and, we are committed to supporting these innovative efforts to benefit scientific labs and medical clinics," said NHGRI director Francis S. Collins, M.D., Ph.D.

Related Links:
EGAPP
CDC
NIH


Gold Member
Turnkey Packaging Solution
HLX
Automated Blood Typing System
IH-500 NEXT
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay

Print article

Channels

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.